These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 36991275)

  • 1. The Metabolic Landscape of Breast Cancer and Its Therapeutic Implications.
    Jiao Z; Pan Y; Chen F
    Mol Diagn Ther; 2023 May; 27(3):349-369. PubMed ID: 36991275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic Reprogramming in Breast Cancer and Its Therapeutic Implications.
    Gandhi N; Das GM
    Cells; 2019 Jan; 8(2):. PubMed ID: 30691108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic reprogramming of cancer-associated fibroblasts by TGF-β drives tumor growth: connecting TGF-β signaling with "Warburg-like" cancer metabolism and L-lactate production.
    Guido C; Whitaker-Menezes D; Capparelli C; Balliet R; Lin Z; Pestell RG; Howell A; Aquila S; Andò S; Martinez-Outschoorn U; Sotgia F; Lisanti MP
    Cell Cycle; 2012 Aug; 11(16):3019-35. PubMed ID: 22874531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic regulation of tumor metabolic reprogramming.
    Tarrado-Castellarnau M; de Atauri P; Cascante M
    Oncotarget; 2016 Sep; 7(38):62726-62753. PubMed ID: 28040803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function.
    Martinez-Outschoorn U; Sotgia F; Lisanti MP
    Semin Oncol; 2014 Apr; 41(2):195-216. PubMed ID: 24787293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reprogramming of Lipid Metabolism Mediates Crosstalk, Remodeling, and Intervention of Microenvironment Components in Breast Cancer.
    Wang J; Zhang W; Liu C; Wang L; Wu J; Sun C; Wu Q
    Int J Biol Sci; 2024; 20(5):1884-1904. PubMed ID: 38481820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic reprogramming: the emerging concept and associated therapeutic strategies.
    Yoshida GJ
    J Exp Clin Cancer Res; 2015 Oct; 34():111. PubMed ID: 26445347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Metabolic Mechanisms of Breast Cancer Metastasis.
    Wang L; Zhang S; Wang X
    Front Oncol; 2020; 10():602416. PubMed ID: 33489906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic crosstalk in the breast cancer microenvironment.
    Dias AS; Almeida CR; Helguero LA; Duarte IF
    Eur J Cancer; 2019 Nov; 121():154-171. PubMed ID: 31581056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic reprogramming and crosstalk of cancer-related fibroblasts and immune cells in the tumor microenvironment.
    Zhu Y; Li X; Wang L; Hong X; Yang J
    Front Endocrinol (Lausanne); 2022; 13():988295. PubMed ID: 36046791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crosstalk between Hypoxia and Extracellular Matrix in the Tumor Microenvironment in Breast Cancer.
    Dekker Y; Le Dévédec SE; Danen EHJ; Liu Q
    Genes (Basel); 2022 Sep; 13(9):. PubMed ID: 36140753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The interferon-inducible protein viperin controls cancer metabolic reprogramming to enhance cancer progression.
    Choi KM; Kim JJ; Yoo J; Kim KS; Gu Y; Eom J; Jeong H; Kim K; Nam KT; Park YS; Chung JY; Seo JY
    J Clin Invest; 2022 Dec; 132(24):. PubMed ID: 36227691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic metabolic reprogramming in breast cancer: focus on signaling pathways and mitochondrial genes.
    Malayil R; Chhichholiya Y; Vasudeva K; Singh HV; Singh T; Singh S; Munshi A
    Med Oncol; 2023 May; 40(6):174. PubMed ID: 37170010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
    Gong T; Cui L; Wang H; Wang H; Han N
    J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of flavonoids targeting PI3K/Akt/HIF-1α signaling pathway in therapy-resistant cancer cells - A potential contribution to the predictive, preventive, and personalized medicine.
    Mazurakova A; Koklesova L; Csizmár SH; Samec M; Brockmueller A; Šudomová M; Biringer K; Kudela E; Pec M; Samuel SM; Kassayova M; Hassan STS; Smejkal K; Shakibaei M; Büsselberg D; Saso L; Kubatka P; Golubnitschaja O
    J Adv Res; 2024 Jan; 55():103-118. PubMed ID: 36871616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes.
    Wang J; Duan Z; Nugent Z; Zou JX; Borowsky AD; Zhang Y; Tepper CG; Li JJ; Fiehn O; Xu J; Kung HJ; Murphy LC; Chen HW
    Cancer Lett; 2016 Aug; 378(2):69-79. PubMed ID: 27164560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ROS/PI3K/Akt and Wnt/β-catenin signalings activate HIF-1α-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer.
    Dong S; Liang S; Cheng Z; Zhang X; Luo L; Li L; Zhang W; Li S; Xu Q; Zhong M; Zhu J; Zhang G; Hu S
    J Exp Clin Cancer Res; 2022 Jan; 41(1):15. PubMed ID: 34998404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reprogramming Carbohydrate Metabolism in Cancer and Its Role in Regulating the Tumor Microenvironment.
    Adhikari S; Guha D; Mohan C; Mukherjee S; Tyler JK; Das C
    Subcell Biochem; 2022; 100():3-65. PubMed ID: 36301490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of adipocytes in the tumor microenvironment to breast cancer metabolism.
    Lyu X; Zhang Q; Fares HM; Wang Y; Han Y; Sun L
    Cancer Lett; 2022 May; 534():215616. PubMed ID: 35248624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting LIN28B reprograms tumor glucose metabolism and acidic microenvironment to suppress cancer stemness and metastasis.
    Chen C; Bai L; Cao F; Wang S; He H; Song M; Chen H; Liu Y; Guo J; Si Q; Pan Y; Zhu R; Chuang TH; Xiang R; Luo Y
    Oncogene; 2019 Jun; 38(23):4527-4539. PubMed ID: 30742065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.